AdAlta Ltd (ASX:1AD) managing director Tim Oldham sits down with Proactive’s Jonathan Jackson to discuss encouraging outcomes from a Phase I extension study of their lead asset, AD-214, aimed at combating Idiopathic Pulmonary Fibrosis (IPF). This pivotal study assessed the target Phase II dose of AD-214 in healthy volunteers, marking a significant milestone in the drug's development pathway. The study's positive results have addressed the inquiries of potential partners. AD-214 exhibited a commendable safety profile, with consistent pharmacokinetics (PK) and pharmacodynamics (PD) across all doses and participants. This consistency bolsters confidence in the selected dose for Phase II studies. There was no evidence of adverse effects that could undermine efficacy, even with prolonged use, highlighting AD-214's potential as a treatment for IPF. With these results in hand, AdAlta is now engaging with a pipeline of potential partners to discuss licensing or asset financing transactions. Such agreements would provide the necessary support for the start of Phase II trials.
AdAlta delivers positive Phase I Extension Study results for AD-214
